Focused On-demand Library for Transcription initiation factor IIA subunit 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P52657

UPID:

T2AG_HUMAN

Alternative names:

General transcription factor IIA subunit 2; TFIIA p12 subunit; Transcription initiation factor IIA gamma chain

Alternative UPACC:

P52657; A8MYQ7; Q6FGB5

Background:

Transcription initiation factor IIA subunit 2 (TFIIA p12 subunit) is a pivotal component of the RNA polymerase II transcription machinery. It plays a crucial role in transcriptional activation by forming a complex with TBP, thereby mediating transcriptional activity. Known by alternative names such as General transcription factor IIA subunit 2 and Transcription initiation factor IIA gamma chain, this protein is essential for the regulation of gene expression.

Therapeutic significance:

Understanding the role of Transcription initiation factor IIA subunit 2 could open doors to potential therapeutic strategies. Its critical function in transcriptional activation positions it as a key target for research aimed at modulating gene expression in various diseases.